The purpose of the study is to evaluate the safety and tolerability of a 30-week aerobicexercise therapy program in cancer patients recovering from COVID-19. The study will lookat whether the aerobic exercise therapy causes few or mild side effects in participants.Aerobic exercise is physical activity that uses the large muscle groups (muscles in yourlegs, buttocks, back, and chest) and can be performed for several minutes at a time. Theaerobic exercise therapy being used in this study will be a walking program that will beadjusted so it matches participant fitness levels (how much exercise you can handle).
Not Provided
Other: Aerobic Exercise Therapy
Aerobic Exercise Therapy/AT will consist of 30 weeks of treadmill walking sessions. AT
will consist of supervised, individualized walking delivered up to 6 times weekly (over a
7-day period) to achieve a cumulative total duration ranging from 90 mins/wk up to 375
mins/wk following a non-linear dosing schedule. The planned dose and scheduling of AT
will be continually altered and progressed in conjunction with appropriate rest/recovery
sessions across the entire intervention period (i.e., non-linear periodized schedule).
Other Name: AT
Inclusion Criteria:
- Age ≥ 18
- Previously admitted to a hospital for Covid-19
- Discharged from hospital for at least 30 days
- Previously treated for cancer at MSK
- Interval of ≥ 12 months but ≤ 10 years following completion of primary non-hormonal
anti-cancer therapy (current endocrine therapy and maintenance therapy allowed)
- Space to house a treadmill at personal residence
- Cleared for exercise participation as per screening clearance via the Physical
Activity Readiness Questionnaire (PAR-Q+)
- Performing less than 90 minutes of structured moderate-intensity or
strenuous-intensity exercise per week, as evaluation by self-report
- If a female of child-bearing potential, must not be pregnant or planning to become
pregnant during the study.
- Women <50 years old who are of child-bearing potential must have a negative
pregnancy test within 14 days of enrollment.
Exclusion Criteria:
- Currently receiving home oxygen after discharge
- Enrollment onto any other interventional investigational study
- Current treatment for any other diagnosis of invasive cancer of any kind
- Distant metastatic malignancy of any kind
- Receiving non-hormonal anticancer therapy
- Any other condition or intercurrent illness that, in the opinion of the
investigator, makes the subject a poor candidate for study participation
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)
Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States
Jessica Scott, PhD, Principal Investigator
Memorial Sloan Kettering Cancer Center